Kinesin

Kinesin Related Products (58):

By Effects:	Control (1) Inhibitors (52) Activator (1) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-132840

Sovilnesib	Inhibitor	99.89%
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC₅₀ value of 0.071 μM. Sovilnesib can be used for the research of cancer.

HY-101770

BTB-1	Inhibitor	99.75%
BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC₅₀ of 1.69 μM.

HY-153065

KIF18A-IN-6	Inhibitor	98.56%
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC₅₀ of 0.016 μM against KIF18A microtubule-dependent ATPase activity.

HY-144894

AM-5308	Inhibitor	99.26%
AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).

HY-112777

Kinesore	Modulator	≥98.0%
Kinesore is an inhibitor of the KLC2-SKIP Interaction.

HY-115570A

(Z/E)-GW406108X	Inhibitor
(Z/E)-GW406108X is a mixture of different configurations of GW406108X (HY-115570). GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM.

HY-162937

KIF18A-IN-13	Inhibitor
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer.

HY-164978

KIF18A-IN-14	Inhibitor
KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC₅₀s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.

HY-145034

KIF18A-IN-1	Inhibitor	98.39%
KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.

HY-13224

AZD4877	Inhibitor	99.49%
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC₅₀ of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.

HY-115570

GW406108X	Inhibitor	≥98.0%
GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC₅₀ of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.

HY-153066

VLS-1272	Inhibitor	98.09%
VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC₅₀ = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN^High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research.

HY-110208

BRD9876		98.82%
BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research.

HY-160441

MC-Val-Cit-PAB-Ispinesib	Inhibitor	99.85%
MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent inhibitor of Eg5. MC-Val-Cit-PAB-Ispinesib is a click chemistry reagent.

HY-145803

KIF18A-IN-3	Inhibitor	99.30%
KIF18A-IN-3 is a potent KIF18A inhibitor (IC₅₀=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer.

HY-162110

AM-9022	Inhibitor	99.48%
AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.

HY-15187A

(R)-Filanesib	Inhibitor	98.80%
(R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC₅₀ of 6 nM.

HY-145802

KIF18A-IN-2	Inhibitor	99.34%
KIF18A-IN-2 is a potent KIF18A inhibitor (IC₅₀=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer.

HY-14846A

Litronesib Racemate		99.20%
Litronesib Racemate (LY2523355 Racemate) is the racemate of litronesib. Litronesib is a selective, allosteric inhibitor of kinesin Eg5.

HY-118961

SR31527 chloride	Inhibitor
SR31527 chloride is a potent KIFC1 inhibitor with an IC₅₀ value of 6.6 µM. SR31527 chloride decreases cell viability and colony formation.

Name
Email *

	Sorry, but the email address you supplied was invalid.